Watchlist

Watchlist
AbbVie Inc. (ABBV)
3 Things In Biotech You Should Learn Today: December 13, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AbbVie spikes the ball at ASH 2017 Company: AbbVie ( ABBV ) and Roche ( RHHBY ) Therap…
Why Tech Still Looks So Attractive
Introduction - tech on the mend "Tech" is almost always in fashion when the economy is expanding. In the late 1800s, for example, steel production involved high technology. The application of technology to oil extraction allowed the Oil Age to flourish. Today, when we talk about tech, we g…
Combination of AbbVie's venetoclax and Rituxan successful in late-stage leukemia study
A Phase 3 clinical trial, MURANO, assessing AbbVie's ( ABBV -1.1% ) VENCLEXTA/VENCYXTO (venetoclax) combined with Roche unit ( OTCQX:RHHBY ) Genentech's Rituxan (rituximab) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) showed a treatment benefit compared to bend…
AbbVie Announces Phase 3 Study of VENCLEXTA(TM)/ VENCLYXTO(TM) (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint
NORTH CHICAGO, Ill. , Dec. 12, 2017 /PRNewswire/ --AbbVie (NYSE: ABBV), a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Phase 3…
Buy Celgene And Regeneron On The Dips As Insiders Are Buying
According to SEC Form 4 filings between October 25 to December 4, 2017, insiders at Celgene Corp. (NASDAQ: CELG ), one of the top five constituents of the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ), bought a total of 84,870 shares at prices between $31.21 per share and $98.17 per shar…
IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition
NORTH CHICAGO, Ill. , Dec. 11, 2017 /PRNewswire/ --AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data on the biologic and cellular mechanisms of IMBRUVICA (ibrutinib) in patients with chronic graft-versus-host disease (cGVHD), a potentially life-…
Dividend Income Update November 2017
The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest…
IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
NORTH CHICAGO, Ill. , Dec. 9, 2017 /PRNewswire/ --AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced pooled analysis results of the longest follow-up data to date in Bruton's tyrosine kinase (BTK) inhibition for relapsed/refractory (R/R) mantle cell lymphoma (M…
IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients
NORTH CHICAGO, Ill. , Dec. 9, 2017 /PRNewswire/ --AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new three-year follow-up data from the RESONATE -2 study (PCYC-1115/1116), which found that previously-untreated chronic lymphocytic leukemia/small lym…
Biotech Analysis Central Pharma News: Madrigal's NASH Success, AbbVie's Phase 3 Win, Juno's Collaboration
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Madrigal Achieves Primary Endpoint In Biopsy-Proven NASH In Phase 2 Trial News: Madrigal Pharmaceuticals ( MDGL ) announced that it had achieved t…
Buy Biotech ETF IBB And Trim Semiconductor Stocks
The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ), which tracks the Nasdaq Biotechnology Index (NASDAQ: NBI ), has been in and out of bear market territory, defined as a drop of 20% or more from its peak, since September 2015 when then-Presidential candidate Hillary Clinton sent out a tweet…
AbbVie Inc. (ABBV)